Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Surgical resection and metastasectomy

4 evidence topics · 4 sources

ASCO guideline: revision resection and local ablative treatment of limited metastases

“In the setting of resectable, recurrent locoregional disease and no distant metastatic disease, regardless of prior treatment type, patients should be offered revision resection and appropriate surgical reconstruction and rehabilitation.” (opens the source at this quote in a new tab)

“In the setting of resectable, recurrent locoregional disease and distant metastatic disease, regardless of prior treatment type, treatment may include palliative revision resection and appropriate surgical reconstruction and rehabilitation, if the metastatic disease is not rapidly progressive or imminently lethal.” (opens the source at this quote in a new tab)

“In the setting of ACC and/or low-grade tumors with indolent biology with limited metastases (ie, ≤5 metastases), local ablative treatments such as surgery (metastatectomy) or stereotactic body radiation therapy may be offered to delay local disease progression.” (opens the source at this quote in a new tab)

ESMO-EURACAN guideline: lung metastasectomy in selected patients

“Lung metastasectomy should be considered in patients without other R/M tumour deposits, provided that a complete surgical resection is feasible and disease-free interval from primary diagnosis is >36 months.” (opens the source at this quote in a new tab)

“In one study, a prolonged disease-free interval (>36 months) and radical resection were the main prognostic factors in 109 patients with AdCC and lung metastases who underwent metastasectomy.” (opens the source at this quote in a new tab)

Lung metastasectomy outcomes in 109 patients

“The cumulative survival was 66.8% at 5years and 40.5% at 10years. In patients with a disease-free interval (DFI) greater than 36months, the overall survival was 76.5% at 5years. Survival in case of complete surgical resection was 69.5% at 5years.” (opens the source at this quote in a new tab)

“Lung metastasectomy should be considered as a therapeutic option to achieve local control of disease when 2 conditions are met: (1) complete surgical resection is feasible and (2) the time to pulmonary relapse after primary tumor treatment is greater than 36months.” (opens the source at this quote in a new tab)

Pulmonary metastasis-directed local therapy and overall survival: 219 participants

“Of 219 included ACC, 119 (54%) had no PM‐LT and 100 (46%) did. PM‐LT patients had more nonsolid histology (p = .0008), oligometastases (p < .0001), exclusively PM (p = .02), and longer time to metastasis from diagnosis (p < .0001).” (opens the source at this quote in a new tab)

“On univariate and multivariate analysis, PM‐LT did not increase OS at any time point for nonsolid ACC.” (opens the source at this quote in a new tab)

“Findings suggest PM‐LT does not increase OS in unselected ACC.” (opens the source at this quote in a new tab)